uniQure (NASDAQ:QURE) CFO Sells $108,720.00 in Stock

uniQure N.V. (NASDAQ:QURE) CFO Christian Klemt sold 12,000 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total transaction of $108,720.00. Following the completion of the sale, the chief financial officer owned 226,581 shares of the company’s stock, valued at approximately $2,052,823.86. This represents a 5.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Christian Klemt also recently made the following trade(s):

• On Wednesday, February 25th, Christian Klemt sold 6,217 shares of uniQure stock. The stock was sold at an average price of $23.86, for a total value of $148,337.62.

uniQure Stock Up 34.0%

NASDAQ:QURE opened at $14.27 on Monday. uniQure N.V. has a 1 year low of $7.76 and a 1 year high of $71.50. The stock has a 50-day moving average price of $22.04 and a two-hundred day moving average price of $29.63. The stock has a market cap of $892.30 million, a price-to-earnings ratio of -4.14 and a beta of 0.73. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.25.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.37. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%.The company had revenue of $5.57 million for the quarter, compared to analyst estimates of $4.84 million. As a group, equities analysts expect that uniQure N.V. will post -3.75 earnings per share for the current year.

Analyst Ratings Changes

QURE has been the topic of a number of research reports. Leerink Partners reaffirmed an “outperform” rating and issued a $35.00 price target on shares of uniQure in a research note on Monday, March 2nd. Wells Fargo & Company reissued an “equal weight” rating and set a $15.00 price objective (down from $60.00) on shares of uniQure in a research report on Tuesday, March 3rd. Sanford C. Bernstein lowered shares of uniQure to a “market perform” rating in a report on Tuesday, March 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of uniQure in a research report on Wednesday, January 21st. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $9.00 target price (down from $55.00) on shares of uniQure in a research note on Monday, March 2nd. Seven analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, uniQure currently has a consensus rating of “Hold” and a consensus price target of $34.33.

Hedge Funds Weigh In On uniQure

Hedge funds have recently made changes to their positions in the business. Private Trust Co. NA acquired a new stake in shares of uniQure in the third quarter valued at approximately $28,000. Jones Financial Companies Lllp lifted its position in shares of uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 509 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in uniQure by 5.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock worth $243,000 after purchasing an additional 533 shares during the last quarter. Arizona State Retirement System boosted its holdings in uniQure by 6.0% during the fourth quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock worth $267,000 after purchasing an additional 627 shares during the last quarter. Finally, Ensign Peak Advisors Inc grew its position in uniQure by 21.7% in the fourth quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock valued at $87,000 after purchasing an additional 650 shares in the last quarter. 78.83% of the stock is owned by institutional investors.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Neutral Sentiment: Mizuho issued a neutral rating on QURE, keeping some analyst coverage tepid rather than bullish. Read More.
• Negative Sentiment: A senior FDA official publicly called uniQure’s Huntington’s disease therapy unsuccessful and defended the agency’s call for a new randomized, placebo‑controlled study — a move that raises the likelihood of delays and additional trials before any BLA. Read More.
• Negative Sentiment: Broad media coverage amplifies regulatory risk: multiple outlets (WSJ, CNBC, FierceBiotech, BioSpace) report public rebukes from FDA/HHS and intensifying back‑and‑forth with uniQure — increasing reputational and approval uncertainty. Read More.
• Negative Sentiment: Numerous class‑action and shareholder‑lawsuit notices filed and circulated by law firms (lead‑plaintiff deadline April 13, 2026) — these raise potential legal liability, management distraction, and ongoing downward pressure on the share price. Read More.
• Negative Sentiment: Analyst actions have turned negative: Chardan cut its price target and other outlets report pessimistic forecasts (Goldman Sachs coverage noted), contributing to recent downgrades and reduced sell‑side enthusiasm. Read More.
• Negative Sentiment: Multiple insiders (including the CEO and CFO) sold shares on March 4 at ~$9.06 — the CEO, CFO and other insiders reduced holdings by low single‑digit to ~5% amounts. Insider selling can be perceived negatively by the market even though insiders still hold large positions. Read More.
• Negative Sentiment: Short‑term price shock: Zacks and other outlets report the stock plunged ~32% in a week after the FDA said AMT‑130 Phase I/II data are insufficient as primary evidence for a marketing application — underscores how quickly regulatory comments can swing valuation. Read More.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.